» Articles » PMID: 32127527

Serum Free Light Chain Level at Diagnosis in Myeloma Cast Nephropathy-a Multicentre Study

Overview
Journal Blood Cancer J
Date 2020 Mar 5
PMID 32127527
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Myeloma cast nephropathy (MCN) is a common cause of severe renal impairment in multiple myeloma (MM). The level of free light chain (FLC) that causes MCN varies substantially and there is uncertainty about the threshold level that should be used to inform clinical practice. In a multicentre cohort study of 103 patients with a diagnosis of MM and biopsy-confirmed MCN made between 2002-2014, we report prospectively measured levels of serum FLC at diagnosis obtained using a single nephelometric assay (Freelite®) and we explore the relationship between serum FLC level at diagnosis with renal outcome and patient survival. Using a landmark approach, overall survival (OS) was compared between patients who achieved independence from dialysis compared to those who remained dialysis dependent at 3-month, 6-month, 9-month, and 12-month time points. The median serum FLC level at diagnosis was 7531 mg/L (range 107-114600). Serum creatinine was 535 μmol/L (range 168-2993) and eGFR 7 ml/min/1.73 m (range 1-34). Six patients (5.8%) had an FLC level <1500 mg/L, which is the International Myeloma Working Group threshold for MCN and two patients were below the International Kidney and Monoclonal Gammopathy working group threshold of 500 mg/L; one was hypercalcaemic, and one had high-normal serum calcium level and had received a non-steroidal anti-inflammatory agent. Sixty-nine (67%) patients required haemodialysis treatment of whom 36 (52.1%) recovered independent renal function. Sixty-six (64%) patients died with a median OS of 2.5 years (95% CI 1.8-3.3). A landmark analysis revealed that independence from dialysis was associated with improved survival at 3-months (P = 0.003), 6-months (P = 0.035) and 9-months (P = 0.014); there was no survival benefit observed beyond 12 months (P = 0.146). Serum FLC level at diagnosis was neither associated with renal function recovery nor with OS. This is the largest reported cohort of patients with biopsy-confirmed MCN and prospectively measured serum FLC levels. These results indicate that a serum monoclonal FLC > 500 mg/L should be considered the threshold level associated with the development of MCN.

Citing Articles

Toll-like receptor 1/2 activation reduces immunoglobulin free light chain production by multiple myeloma cells in the context of bone marrow stromal cells and fibronectin.

Abdi J, Redegeld F PLoS One. 2025; 20(1):e0310395.

PMID: 39874349 PMC: 11774389. DOI: 10.1371/journal.pone.0310395.


Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study.

Mancuso K, Mina R, Rocchi S, Antonioli E, Petrucci M, Fazio F Cancer Med. 2024; 13(22):e70266.

PMID: 39587728 PMC: 11588855. DOI: 10.1002/cam4.70266.


Triple monoclonal protein-related kidney lesions in a patient with plasma cell dyscrasia: a case report.

Alvi A, Gallan A, Klomjit N Front Nephrol. 2024; 4:1399977.

PMID: 39583089 PMC: 11582032. DOI: 10.3389/fneph.2024.1399977.


Reference interval of free light chains ratio in patients with end-stage renal disease on chronic hemodialysis.

Pena C, Valjalo R, Perez R, Alvarez M, Bustamante P, Forray E Haematologica. 2024; 109(11):3751-3754.

PMID: 39021229 PMC: 11532703. DOI: 10.3324/haematol.2024.285093.


Multiple Myeloma: A Review of the Literature and a Case Report Highlighting the Immunocompromised State of Myeloma Patients.

Nightingale B, Decker M, Ryan R, Kaczmarczyk K, Jandir P, Waykole T World J Oncol. 2024; 15(3):348-354.

PMID: 38751697 PMC: 11092413. DOI: 10.14740/wjon1780.


References
1.
Augustson B, Begum G, Dunn J, Barth N, Davies F, Morgan G . Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005; 23(36):9219-26. DOI: 10.1200/JCO.2005.03.2086. View

2.
Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens X, Montoto S . Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998; 158(17):1889-93. DOI: 10.1001/archinte.158.17.1889. View

3.
Knudsen L, Hjorth M, Hippe E . Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000; 65(3):175-81. DOI: 10.1034/j.1600-0609.2000.90221.x. View

4.
Kyle R, Gertz M, Witzig T, Lust J, Lacy M, Dispenzieri A . Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78(1):21-33. DOI: 10.4065/78.1.21. View

5.
Knudsen L, Hippe E, Hjorth M, Holmberg E, Westin J . Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol. 1994; 53(4):207-12. DOI: 10.1111/j.1600-0609.1994.tb00190.x. View